Ilmarinen Mutual Pension Insurance Co Has $33.24 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Ilmarinen Mutual Pension Insurance Co raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 33.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 63,900 shares of the medical research company's stock after buying an additional 16,000 shares during the quarter. Ilmarinen Mutual Pension Insurance Co's holdings in Thermo Fisher Scientific were worth $33,243,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Legacy Investment Solutions LLC acquired a new position in Thermo Fisher Scientific during the third quarter worth $26,000. Barrett & Company Inc. acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $28,000. FPC Investment Advisory Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $28,000. Missouri Trust & Investment Co bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $29,000. Finally, Pillar Financial Advisors LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter worth $29,000. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

TMO has been the topic of several research analyst reports. Raymond James restated an "outperform" rating and issued a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. UBS Group raised their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a report on Friday, January 31st. Wells Fargo & Company increased their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Finally, Barclays cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $647.09.

Remove Ads

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares of the company's stock, valued at $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 in the last 90 days. Insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO traded down $21.75 during trading on Thursday, hitting $431.81. 2,242,351 shares of the stock traded hands, compared to its average volume of 1,683,692. The business has a 50 day moving average price of $516.75 and a 200 day moving average price of $541.75. The company has a market cap of $162.90 billion, a price-to-earnings ratio of 26.06, a PEG ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a twelve month low of $409.85 and a twelve month high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.